Hyloris Pharmaceuticals prepared to go public

Belgian specialty pharmaceutical company Hyloris Pharmaceuticals SA is getting ready to launch an Initial Public Offering at Euronext Brussels.

Read more

NodThera bags US$55m in Series B round

NodThera, a Scotch spin-out of Polish Selvita developing oral blockers of the NLRP3 inflammasome blockers, has filled up its cashbox with a US$55m investement.

Read more

Bacterial colonisation differs by tumour type

An analysis of 1.500 tumours demonstrates that different human tumour types each harbour their own unique bacterial communities.

Read more

Novo Holdings invests into AI CRO ExScientia

Novo Holdings leads the current US$60m Series C round of ExScientia Ltd, the world-leading artificial intelligence (AI)-driven drug discovery company.

Read more

Poxel SA raises €17.7m through capital increase

Metabolic disease specialist Poxel SA has announced a private placement of 2,358,483 new ordinary shares at €0.02 per share reserved to specified investors.

Read more

British scientists start Phase II on COVID-19 vaccine

Researchers at the University Oxford and AstraZeneca have started enrolment for a Phase II/III trial to test a COVID-19 vaccine in 10,000 volunteers.

Read more

Vaccine to protect from any viral infection

Two companies have presented a novel vaccination concept that might protect risk groups from new SARS-CoV-2 variants.

Read more